SBFM
NASDAQSunshine Biopharma Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$1.16+0.01 (+0.87%)
04:00 PM07:00 PM
News · 26 weeks31+150%
2026-02-082026-08-02
Mix2290d
- SEC Filings9(41%)
- Market9(41%)
- Other4(18%)
Latest news
25 items- SECSunshine Biopharma Inc. filed SEC Form 8-K: Other Events8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSHealth Canada Approves Sunshine Biopharma's Ondansetron for Treatment of Chemotherapy-Induced Nausea and VomitingFORT LAUDERDALE, FL / ACCESS Newswire / July 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Ondansetron tablets of 4mg and 8mg for the Canadian market. Ondansetron is the generic equivalent of the brand name, Zofran®.Ondansetron is highly prescribed for nausea and vomiting caused by cancer chemotherapy, radiation therapy, and surgery. Ondansetron is a prescription serotonin 5-HT3 receptor antagonist. It works by blocking the actions of chemicals in the body that trigger nausea and vomiting. By offering both standard film-coated
- SECSEC Form 424B5 filed by Sunshine Biopharma Inc.424B5 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma and University of Arizona Publish Significant New Research FindingsFORT LAUDERDALE, FL / ACCESS Newswire / July 20, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications today announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor, MR1-114, with nanomolar potency in at least three variants of the SARS-CoV-2 virus in vitro. MR1-114 was found to be efficacious in a mouse model of SARS-CoV-2 infection by repeated oral administration. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS Coron
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Receives Canadian Regulatory Approval for Generic Arimidex(R)FORT LAUDERDALE, FL / ACCESS Newswire / June 25, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Anastrozole tablets of 1mg for the Canadian market. Anastrozole is the generic equivalent of the brand name breast cancer drug, Arimidex®.Anastrozole is a highly prescribed non-steroidal aromatase inhibitor. It works by lowering estrogen levels in the body to slow down or reverse the growth of specific breast tumors. Anastrozole is standard care for the adjuvant treatment of postmenopausal women with hormone receptor-positive breast canc
- SECSEC Form DEF 14C filed by Sunshine Biopharma Inc.DEF 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoagulant, Xarelto®.Rivaroxaban is a direct oral anticoagulant prescribed to treat and prevent deep vein thrombosis and pulmonary embolism. It is also widely utilized to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.The global market for Rivaroxaban is es
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form PRE 14C filed by Sunshine Biopharma Inc.PRE 14C - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Announces Issuance of U.S. Patent 12,624,066 B2 Covering Novel Coronavirus Treatment TechnologyFORT LAUDERDALE, FL / ACCESS Newswire / May 29, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication.The patent covers a series of small molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target a critical vi
- NEWSSunshine Biopharma Announces Reverse Stock Split to Maintain NASDAQ ListingFORT LAUDERDALE, FL / ACCESS Newswire / May 28, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, today announced a one for ten reverse split of its common stock, effective at market open on June 1, 2026. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The reverse stock split will reduce the Company's issued and outstanding shares of common stock from 21,236,346 to approximately 2,123,635.About Sunshine Biopharma Inc.Sunshine Biopharma currently has 60 generic prescription drugs on the market in Canada and
- SECSEC Form SCHEDULE 13G filed by Sunshine Biopharma Inc.SCHEDULE 13G - Sunshine Biopharma Inc. (0001402328) (Subject)
- NEWSSunshine Biopharma Receives Canadian Regulatory Approval for Generic AmoxicillinFORT LAUDERDALE, FL / ACCESS Newswire / May 21, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Amoxicillin formulation for the Canadian market. This strategic expansion reinforces Sunshine Biopharma's commitment to providing affordable, high-quality antibiotics to patients across Canada.Amoxicillin, a widely prescribed penicillin-class antibiotic, is used to treat a variety of bacterial infections including ear infections, sinus infections, strep throat, pneumonia, bronchitis, urinary tract infections, skin and soft‑tissue infectio
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering$6.0 million upfront with up to an additional approximately $12.0 million of potential aggregate gross proceeds upon the exercise in full of warrants. FORT LAUDERDALE, FL / ACCESS Newswire / May 19, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the closing of its previously announced public offering made on a reasonable best efforts basis with gross proceeds to the Company of approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consisted of 12,000,000 Co
- SECSEC Form 424B4 filed by Sunshine Biopharma Inc.424B4 - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form EFFECT filed by Sunshine Biopharma Inc.EFFECT - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Inc. Announces Pricing of $6.0 Million Public OfferingFORT LAUDERDALE, FL / ACCESS Newswire / May 18, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The offering consisted of 12,000,000 Common Units (or Pre-Funded Units), each consisting of (i) one (1) share of Common Stock or one (1) Pre-Funded Warrant and (ii) two (2) Series C Warrants to purchas
- SECSEC Form 10-Q filed by Sunshine Biopharma Inc.10-Q - Sunshine Biopharma Inc. (0001402328) (Filer)
- SECSEC Form S-1 filed by Sunshine Biopharma Inc.S-1 - Sunshine Biopharma Inc. (0001402328) (Filer)
- INSIDERSEC Form 4 filed by Natan David4 - Sunshine Biopharma Inc. (0001402328) (Issuer)
- SECSunshine Biopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Sunshine Biopharma Inc. (0001402328) (Filer)
- NEWSSunshine Biopharma Reports Fiscal 2025 Revenue of $36.3 Million, a 4.1% Increase Over Prior YearFORT LAUDERDALE, FL / ACCESS Newswire / April 6, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) ("Sunshine Biopharma" or the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the filing of its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025.2025 HighlightsRevenue of $36.3 million, representing a 4.1% increase compared to 2024.$2.46 million in gross proceeds raised through a registered direct offering to support expansion of sales operations.Nine new generic prescription drugs launched, expanding the Company's portfolio in oncology, cardiovascular health, central
SBFM FAQ
5 questionsWhat does Sunshine Biopharma Inc. do?
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a...Where does SBFM stock trade?
Sunshine Biopharma Inc. (SBFM) is listed on NASDAQ.What sector and industry is SBFM in?
Sunshine Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What companies are similar to SBFM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SBFM side-by-side with any of them on Quantisnow.How can I track SBFM on Quantisnow?
Quantisnow aggregates Sunshine Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SBFM to receive live email and push alerts on every new disclosure.